Background: Identifying factors associated with mortality for HIV-infected patients with persistent viraemia despite antiretroviral (ARV) therapy may inform diagnostic and treatment strategies.
Introduction
The optimal management of extensively antiretroviral (ARV) therapy-experienced HIV-infected persons who remain viraemic despite continued ARV therapy remains a clinical challenge. 1 -4 Identifying factors associated with improved clinical outcomes among such patients can inform ARV treatment strategies. Existing data indicate that ARV resistance among both ARVtreated and ARV-naive persons is associated with an increased risk of death, 5, 6 suggesting that strategies aimed at reducing the induction of resistance may improve survival. As new ARV agents from diverse drug classes become available, routine ARV resistance testing among viraemic treatment-experienced patients has become a standard of care to guide ARV selection. 1,3,7 -9 In this report, using data from the HIV Outpatient Study (HOPS), we evaluated the associations between mortality risk, patient factors and ARV resistance mutations in a diverse group of highly ARV treatment-experienced persons who remained viraemic despite ongoing ARV exposure.
Methods

The HOPS
The HOPS is an ongoing prospective cohort study of HIV-infected adults receiving care at participating HIV clinics. For this analysis, data were included from 12 clinics (university-based, private and public) in eight US cities (Chicago, IL, USA; Denver, CO, USA; Stony Brook, NY, USA; Oakland/ San Leandro, CA, USA; Walnut Creek, CA, USA; Philadelphia, PA, USA; Tampa, FL, USA; and Washington, DC, USA) since 1993. 10 Patient data, including sociodemographic characteristics, diagnoses, treatments and laboratory values, are abstracted from medical charts and entered into an electronic database by trained staff. These data are reviewed for quality and analysed centrally. HOPS investigators have collected information on more than 10 000 patients seen at over 400 000 clinical encounters. The HOPS protocol has been reviewed annually and approved by the CDC (Atlanta, GA, USA), the Cerner Corporation (Vienna, VA, USA) and the institutional review board at each participating site. The study protocol conforms to the guidelines of the US Department of Health and Human Services for the protection of human subjects in research.
Study population and definitions
We analysed data from participants with at least two clinical encounters who met the criteria for triple ARV class failure (TCF; defined below) between 1 January 1999 and 31 December 2008 and contributed observation time during 1 January 1999 to 31 December 2012, using the dataset updated 31 December 2013. We defined triple-class-experienced (TCE) as having received a prescription for ≥4 continuous months of an ARV from each of the three major drug classes [nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), although not necessarily simultaneously]. We limited our analyses to patients who had a plasma HIV RNA level [viral load (VL)] .1000 copies/mL (VL .3.0 log 10 copies/mL) after becoming TCE and while receiving ARV therapy. We defined such patients as TCF. The baseline date was defined as the earliest date at which a VL .1000 copies/mL was seen after meeting the TCE criteria during 1999 -2008. Patients could have met the TCF definition prior to 1999 if they contributed observation time after 1 January 1999. We conducted further analyses for the subset of TCF patients for whom results of HIV genotypic testing performed on or after the baseline date were available, incorporating resistance results from this first postbaseline genotypic testing as well as results from prior resistance testing for these patients.
Thymidine analogue NRTI-associated resistance mutations (TAMs) were M41L, D67N, K70E/R, L210W, T215F/Y and K219E/Q. Novel ARV agents were fusion inhibitors, integrase strand transfer inhibitors, entry inhibitors and CCR5 attachment inhibitors.
Statistical analyses
We used Cox proportional hazards regression models to examine risk factors for mortality among TCF patients. Observation began at baseline, continued until death (if documented within 180 days of last patient contact) and was censored (the patient was assumed to be alive) at the last patient contact plus 180 days if the patient was not known to be deceased by then, or at 31 December 2012, whichever occurred first. Among a subgroup of TCF patients with genotypic resistance testing, we analysed cumulative mutations at first genotypic testing following TCF as well as mutations detected by prior genotypic testing studies. We evaluated the associations between mortality and both the total number and individual types of mutations, after adjusting for other clinical and demographic factors. For these subgroup analyses, the start of observation was reset to the date of the first post-baseline genotypic testing. For both unadjusted and adjusted Cox regression models, the results are reported using hazard ratios (HRs) and 95% CIs.
To develop multivariable regression models for mortality after the start of observation, variables with P values ,0.20 in univariate analyses were considered for inclusion in multivariable models; manual backwards selection was then used to eliminate non-significant variables sequentially in order of highest P value.
We estimated the proportion of the observation time during which patients were viraemic (defined as VL ≥200 copies/mL) by summing the duration of observation times around a given detectable VL; a patient was considered to be viraemic from the mid-point in time between the prior VL test and the 'current' time, to the mid-point in time between the 'current' time and the next VL test. We summed the time spent as viraemic across patients included in the analysis. All the descriptive summaries, survival plots and regression analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA). Statistical significance was defined as a two-sided P value ,0.05 for statistical tests and, for an HR, when the associated 95% CI excluded 1.0.
Results
Of 3840 HOPS patients with at least two clinical encounters between 1 January 1999 and 31 December 2008 and whose ARV prescription history was known, 1536 patients met the definition of TCE; of these, 597 (38.9%) met the definition of TCF. Of the 597 patients, 158 (26.5%) first met the TCF criteria in 1998 or earlier and 439 (73.5%) met them during 1999 -2008. Among the TCF patients, the median baseline age was 41 years, 77.2% were male, 79.9% had a prior diagnosis of AIDS and 79.9% had been exposed to mono or dual ARV therapy prior to their first combination ARV therapy (cART). The median baseline and nadir CD4+ T cell counts were 283 and 105 cells/mm 3 , respectively. Most (71.4%) patients had been prescribed a first cART regimen that was PI-based. The median observation time after baseline was 6.2 years (IQR 3.1-10.5) ( Table 1) .
Of the 597 TCF patients, 115 (19.3%) died (Table 1) , giving a mortality rate of 2.77 deaths per 100 person-years of follow-up. In the final multivariable Cox regression model, age per 10 years (HR 1.61, 95% CI 1.28 -2.02), risk of HIV from use of injection drugs (HR 1.81, 95% CI 1.10 -2.98), baseline CD4+ T cell count ,200 cells/mm 3 (HR 3.68, 95% CI 2.41 -5.62), baseline plasma HIV RNA ≥5.0 log 10 copies/mL (HR 2.91, 95% CI 1.88 -4.49) and having received a first cART regimen that was PI-based (HR 2.44, 95% CI 1.47 -4.06) were associated with an increased risk of death, while receiving a novel ARV agent during follow-up (HR 0.45, 95% CI 0.22 -0.93) was associated with an decreased risk of death (Table 2) .
Among the 597 TCF patients, 556 (93.1%) had a VL measurement that was ≥200 copies/mL after meeting the TCF criteria; these patients remained viraemic above this level during 68% of their post-baseline follow-up. A total of 13/597 (2.2%) of patients had subsequent measurements that were all ,200 copies/mL and 28/597 (4.7%) had no subsequent VL recorded. The 556 viraemic patients had a median of 17 (IQR 8 -29) VL measurements after meeting the TCF criteria, with median and mean durations of viraemia after baseline of 2.7 (IQR 1.1 -4.9) and 3.4 years, respectively. Among the 597 TCF patients, 156 patients received a 'novel' ARV agent (i.e. one other than an NRTI, NNRTI or PI Mortality factors among viraemic ARV-experienced HIV patients 2827 JAC such as raltegravir, maraviroc or enfuvirtide); the mortality rate in these patients after baseline and after starting the novel agent was 0.63 and 1.56 deaths/100 person-years of observation respectively, compared with 3.00 deaths/100 person-years for patients who did not receive a novel agent after baseline. There were 274 patients who underwent genotypic testing after baseline; 47 died (17.2%) within 180 days of their last contact and their mortality rate over the remaining observation was 2.53 deaths/100 person-years. The median time from baseline to the first post-baseline genotypic testing was 12.1 (IQR 3.8 -32.5) months. Among these 274 patients, the median age at baseline was 41 years and most were male (73.4%), had a prior AIDS diagnosis (79.2%) and had been exposed to mono or dual ARV therapy (76.3%) prior to first cART (Table 1) ; their median baseline and nadir CD4+ T cell counts were 289 and 111 cells/mm 3 , respectively. Most (73.0%) had also received a PI-based initial cART regimen. The median observation time after the date of the first post-baseline genotypic testing was 8.1 years (compared with a median observation time of 6.2 years after the baseline date used for the analyses of the entire TCF cohort). In univariate analyses, older age, HIV risk from use of injection drugs, baseline CD4+ cell count ,200 copies/mm 3 , baseline VL ≥5.0 log 10 copies/mL, having exposure to mono or dual ARV therapy before cART therapy and having a PI-based first cART were each associated with an increased mortality risk, while a later year of meeting the TCF criteria (in 1999-2008 versus 1997-1998) was associated with a decreased mortality risk; however, neither the number nor the type of HIV mutations, the number of ARV drug classes against which mutations were present, or number of mutations per ARV class was significantly associated with mortality in univariate analyses ( 
Discussion
In the HOPS, among substantially treatment-experienced patients who remained viraemic despite continuous ARV therapy, risk of death was associated with established clinical factors, including a lower CD4+ T cell count and higher plasma HIV RNA levels. For these patients the use of any 'novel' ARV, including an integrase strand transfer inhibitor, a CCR5 receptor antagonist or a fusion inhibitor, was associated with a reduction in mortality, while the historical use of PI-based initial cART regimens was associated with a greater mortality risk. Among the subset of TCF patients with available HIV genotypic resistance data, contrary to our hypothesis and to some preliminary data (not shown), no genotypic patterns of mutations were independently associated with risk of death. This was true despite the fact that many of the patients whom we studied who were receiving nonsuppressive ARV had had a prior extensive exposure to drugs that are no longer recommended first-line therapies, such as thymidine analogue NRTIs, 11, 12 and had viral isolates demonstrating mutations associated with resistance to some of these older drugs.
Our observation that no increased (or decreased) mortality risk was associated with the presence of genotypic resistance, regardless of the number and types of mutations and whether single or multiple ARVs or classes of ARVs were affected, is in contrast to some recent reports 5, 6 that have identified associations between ARV resistance and risk of death, but it is consistent with one study. 13 Although extensive genotypic resistance may be a marker for patient or virus characteristics that make viral suppression with ARV more difficult, and specific mutational patterns can be associated with increased viral fitness or replication competence, we did not ascertain any associations between the The baseline date was defined as the earliest date during 1999 -2008 when a triple-ARV-class-experienced patient had an HIV VL .1000 copies/mL (log 10 VL .3.0). Additional baseline variables (listed in Table 1 ) were explored in univariate analyses and were not associated with mortality risk; for brevity, only the key demographic characteristics are shown in the table. c The multivariable model contains variables with P,0.20 in univariate analyses, and manual backwards selection was used to eliminate non-significant variables in order of highest P value.
Palella et al. Among our TCF patients and the subset of these with available HIV genotypic data, having received a first cART regimen that contained a PI (versus an NNRTI) was associated with a greater risk of death. While PI-containing initial cART, particularly regimens that include older PIs, can be associated with greater treatment-limiting toxicity, pill burden and lower rates of HIV suppression compared with NNRTI therapies, the association with a subsequent increased mortality among such persons at a timepoint distant from the initial cART, often after multiple cART regimens, is notable.
The use of novel ARV agents among TCF patients was associated with a survival benefit. This was not surprising since the use of such therapies among ARV therapy-experienced patients in randomized prospective clinical trials has been shown to be associated with improved virological and immunological outcomes, 14 -17 yet this cohort is among the first in which a survival benefit associated with the use of these drugs among ARV therapy-experienced patients is apparent.
Greater HIV replication capacity has been associated with mutations known to confer resistance to thymidine analogue NRTIs, notably with ≥4 TAMs. 18 -20 Other data exist indicating that viruses containing fewer TAMs 20, 21 can demonstrate decreased replication capacity and/or RT processivity. Other point mutations selected by ARVs reduce viral fitness in potentially clinically relevant ways that are exploitable among ARV recipients who experience incomplete HIV suppression. 22 -26 However, among our TCF patients, we observed no survival disadvantage associated with having ≥4 TAMS and no survival advantages associated with HIV mutations known to reduce viral fitness, such as M184V.
27,28
While we did not identify any discrete care-related factors that could reasonably have impacted on mortality risk, and that improved in general over time, persons who became TCF in earlier time periods were more likely to have had exposure to mono or dual NRTI therapy (although such exposure was not associated with an increased risk of death in multivariable models). Moreover, the prescribed ARV regimens substantially evolved over time (for both the initial and the salvage regimen), with more persons receiving NNRTI-based first-line therapy and more effective, less toxic background ARVs during later time periods; our findings that a PI-based regimen as first cART was a risk factor for mortality and that the use of novel ARV agents during follow-up was associated with improved survival are consistent with this evolution.
Our analysis has several limitations. Approximately half of the TCF patients had evaluable HIV genotype data. While we cannot readily explain the lack of association with mortality risk (improved or worsened) among persons with extensive resistance mutations, unmeasured confounding (e.g. resistant virus reflecting poor adherence, which was not assessed in this cohort) rather than some direct effect of specific mutational patterns may have been present. Finally, it is possible that we failed to detect associations between specific mutational combinations and mortality due to the relative rarity of these mutations or mutational patterns (a type 2 error). It is reassuring, however, that we did identify positive associations between mortality risk and known validated clinical variables in the overall group of TCF patients, i.e. a lower baseline CD4+ T cell count and higher plasma HIV RNA.
In conclusion, among substantially ARV-experienced HIVinfected participants in the HOPS who remained viraemic despite continued therapy, mortality was associated with established clinical factors and ARV therapy factors (with PI-based initial cART associated with an increased mortality risk and the use of novel agents associated with improved survival), but not the presence of specific HIV drug resistance mutations or mutational patterns. Whether or not our findings are generalizable will require further evaluation in a larger population that includes more deaths, more genotypic HIV resistance tests and perhaps more person-years of observation. Ample data exist supporting the importance of routine HIV resistance testing among virally nonsuppressed ARV treatment-experienced patients 11 in order to characterize the extent and type of ARV resistance present and to optimize ARV drug selection. The multivariable model contains variables with P,0.20 in univariate analysis, and manual backwards selection was used to eliminate non-significant variables in order of highest P value.
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